Furthermore, survival analysis suggested that CIDEA down-regulation indicated poor prognosis in patients with ESCC, indicating that CIDEA has the potential to serve as a novel prognostic biomarker for ESCC patients. This evidence concerns the gene CIDEA and esophageal squamous cell carcinoma.